Latanoprostene Bunod - Latest Advances

The effect of latanoprostene bunod on retinal vessel density in patients with primary open-angle glaucoma.

Journal: European journal of ophthalmology

Published: November 14, 2025

Angina Pectoris Following Latanoprostene Bunod 0.024% Administration: A Case Report.

Journal: Cureus

Published: November 10, 2025

Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study.

Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Published: September 16, 2025

Drugs for open-angle glaucoma.

Journal: The Medical letter on drugs and therapeutics

Published: April 22, 2025

Corrigendum: Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication.

Journal: Medical gas research

Published: April 18, 2025

Evaluation of corneal and anterior segment alterations following short-term use of topical latanoprostene bunod.

Journal: International ophthalmology

Published: March 27, 2025

Investigation of the effect of latanoprostene bunod and latanoprost on peripapillary optical coherence tomography angiography.

Journal: Journal francais d'ophtalmologie

Published: March 25, 2025

Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review.

Journal: Frontiers in ophthalmology

Published: January 02, 2025

Effects of 0.024% latanoprostene bunod on intraocular pressure and pupil diameter in normal cats and cats with congenital glaucoma.

Journal: Veterinary ophthalmology

Published: September 30, 2024

Latanoprostene Bunod 0.024% Early Experience Program (LEEP): A Canadian Initiative for Open-Angle Glaucoma and Ocular Hypertension.

Journal: Ophthalmology and therapy

Published: September 18, 2024

Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study.

Journal: BMC ophthalmology

Published: August 31, 2024

Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication.

Journal: Medical gas research

Published: April 01, 2024